si-bone® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (si) joint. si-bone developed an innovative, patented implant to fuse the si joint. the ifuse implant system® provides a less invasive alternative to traditional sacroiliac (si) joint fusion surgery and has been used in over 25,000 procedures to date. the company is managed by an experienced team of executives from kyphon, medtronic, inbone, saint francis and several start up orthopedic and spine companies. the ifuse implant system is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. this includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. there are potential risks associated with the ifuse implant system. it may not be appropriate for al
Company profile
Ticker
SIBN
Exchange
Website
CEO
Jeffrey Dunn
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
SI-Bone Inc.
SEC CIK
Corporate docs
Subsidiaries
SI-BONE S.R.L. • SI-BONE Deutschland GmbH • SI-BONE UK LTD ...
IRS number
262216351
SIBN stock data
Latest filings (excl ownership)
PRE 14A
Preliminary proxy
18 Apr 24
S-8
Registration of securities for employees
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
26 Feb 24
8-K
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023
8 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
SI-BONE, Inc. Reports Record Financial Results for the Third Quarter 2023 and Raises Annual Guidance
6 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
20 Sep 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance
7 Aug 23
Transcripts
SIBN
Earnings call transcript
2023 Q4
26 Feb 24
SIBN
Earnings call transcript
2023 Q3
6 Nov 23
SIBN
Earnings call transcript
2023 Q2
7 Aug 23
SIBN
Earnings call transcript
2023 Q1
1 May 23
SIBN
Earnings call transcript
2022 Q4
27 Feb 23
SIBN
Earnings call transcript
2022 Q3
8 Nov 22
SIBN
Earnings call transcript
2022 Q2
9 Aug 22
SIBN
Earnings call transcript
2022 Q1
9 May 22
SIBN
Earnings call transcript
2021 Q4
1 Mar 22
SIBN
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
ANTHONY J RECUPERO
4 Apr 24
4
Anshul Maheshwari
4 Apr 24
144
Notice of proposed sale of securities
3 Apr 24
144
Notice of proposed sale of securities
14 Mar 24
4
ANTHONY J RECUPERO
14 Mar 24
4
Mika Nishimura
14 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
LAURA FRANCIS
21 Feb 24
4
JEFFREY W DUNN
21 Feb 24
4
ANTHONY J RECUPERO
21 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 53.49 mm | 53.49 mm | 53.49 mm | 53.49 mm | 53.49 mm | 53.49 mm |
Cash burn (monthly) | 19.11 mm | (no burn) | 3.72 mm | 3.81 mm | 691.00 k | 1.93 mm |
Cash used (since last report) | 127.51 mm | n/a | 24.84 mm | 25.42 mm | 4.61 mm | 12.90 mm |
Cash remaining | -74.02 mm | n/a | 28.65 mm | 28.07 mm | 48.88 mm | 40.60 mm |
Runway (months of cash) | -3.9 | n/a | 7.7 | 7.4 | 70.7 | 21.0 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 152 |
Opened positions | 12 |
Closed positions | 31 |
Increased positions | 71 |
Reduced positions | 40 |
13F shares | Current |
---|---|
Total value | 817.69 bn |
Total shares | 45.07 mm |
Total puts | 6.40 k |
Total calls | 44.10 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Brown Advisory | 3.99 mm | $84.82 bn |
BLK Blackrock | 3.39 mm | $71.91 bn |
First Light Asset Management | 2.52 mm | $53.61 bn |
Vanguard | 2.31 mm | $49.03 bn |
Orbimed Capital | 2.31 mm | $51.20 mm |
Orbimed Advisors | 2.29 mm | $48.69 bn |
Integrated Core Strategies | 2.28 mm | $50.15 mm |
Millennium Management | 1.99 mm | $42.22 bn |
Arboretum Ventures IV | 1.55 mm | $46.27 mm |
Next Century Growth Investors | 1.37 mm | $29.14 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Apr 24 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | Yes | 15.6298 | 920 | 14.38 k | 251,533 |
2 Apr 24 | Anshul Maheshwari | Common Stock | Sell | Dispose S | No | No | 15.4603 | 1,285 | 19.87 k | 205,516 |
2 Apr 24 | Anshul Maheshwari | Common Stock | Sell | Dispose S | No | No | 15.445 | 1,140 | 17.61 k | 206,801 |
2 Apr 24 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | No | 15.5159 | 1,752 | 27.18 k | 252,453 |
2 Apr 24 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | No | 15.4909 | 1,555 | 24.09 k | 254,205 |
13 Mar 24 | Recupero Anthony J | Common Stock | Sell | Dispose S | No | Yes | 16.8237 | 3,330 | 56.02 k | 255,760 |
13 Mar 24 | Mika Nishimura | Common Stock | Sell | Dispose S | No | No | 16.22 | 2,500 | 40.55 k | 19,350 |
2 Feb 24 | Dunn Jeffrey W | Common Stock | Sell | Dispose S | No | No | 20.2968 | 335 | 6.80 k | 44,383 |
News
Needham Reiterates Buy on SI-BONE, Maintains $27 Price Target
3 Apr 24
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights
28 Mar 24
Piper Sandler Initiates Coverage On SI-BONE with Overweight Rating, Announces Price Target of $25
28 Mar 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
27 Feb 24
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $26
27 Feb 24